Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist.
It has been studied for its effectiveness in both glycemic control (for diabetes management) and weight loss.
Clinical trials have shown significant weight loss with tirzepatide. In some studies, participants achieved weight loss of around 15-19% of their initial body weight.
Semaglutide (Wegovy, Ozempic)
Semaglutide is a GLP-1 receptor agonist approved for both diabetes management (Ozempic) and chronic weight management (Wegovy).
In clinical trials for weight loss, participants using semaglutide achieved weight loss of around 14-15% of their initial body weight.
The exact mechanism for weight loss is not fully understood but is believed to involve reduced appetite and increased feelings of fullness.
Liraglutide (Saxenda, Victoza)
Liraglutide is a GLP-1 receptor agonist approved for both diabetes management (Victoza) and weight management (Saxenda).
In weight loss studies, individuals using liraglutide have experienced weight loss ranging from 5-10% of their initial body weight.
Liraglutide is thought to affect the areas of the brain that control appetite, leading to reduced food intake.